Smoking, Symptoms Improvement, and Total Antioxidant Capacity in Patients with Drug-naive First-episode Schizophrenia: A Prospective Cohort Study


Cite item

Full Text

Abstract

Background:It has been hypothesized that smoking is associated with the severity of negative symptoms. Until now, no studies have investigated whether the impact of smoking on negative symptoms is dependent on antioxidants. This study was designed to evaluate the effect of smoking on therapeutic response and total antioxidants capacity (TAOC) in antipsychotic-naïve first-episode (ANFE) patients.

Methods:The severity of the patient’s symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS). A total of 237 ANFE patients were recruited and treated with risperidone (oral tablets, 4-6 mg/day twice a day) for 12 weeks. PANSS was assessed at baseline and a 12-week follow-up. Plasma TAOC levels were also assayed at baseline and week 12.

Results:Relative to nonsmokers with ANFE SZ, smokers had higher PANSS negative subscores. There was no significant difference in TAOC changes after 12 weeks of treatment with risperidone between smokers and non-smokers. However, we found greater improvement in negative symptoms in smokers compared to non-smokers. Further analysis in smokers with SZ demonstrated that improvements in negative symptoms were not associated with changes in TAOC.

Conclusion:Our study suggested that smoking affected the severity of baseline negative symptoms and further contributed to their reduction after risperidone treatment. However, improvement in negative symptoms was not dependent on the changes in TAOC.

About the authors

Zhiyong Gao

, The Affiliated Kangning Hospital of Wenzhou Medical University Zhejiang Provincial Clinical Research Center for Mental Disorder

Email: info@benthamscience.net

Meihong Xiu

, Peking University Huilongguan Clinical Medical School, Beijing Huilongguan Hospital

Email: info@benthamscience.net

Jiahong Liu

, The Affiliated Kangning Hospital of Wenzhou Medical University Zhejiang Provincial Clinical Research Center for Mental Disorder

Email: info@benthamscience.net

Fengchun Wu

Department of Psychiatry,, The Affiliated Brain Hospital of Guangzhou Medical University

Author for correspondence.
Email: info@benthamscience.net

Xiangyang Zhang

Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University

Author for correspondence.
Email: info@benthamscience.net

References

  1. Fang, X.; Chen, Y.; Wang, Y.; Ren, J.; Zhang, C. Depressive symptoms in schizophrenia patients: A possible relationship between SIRT1 and BDNF. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2019, 95, 109673. doi: 10.1016/j.pnpbp.2019.109673 PMID: 31247244
  2. Fang, X.; Chen, Y.; Wang, Y.; Zhang, C. Identification of risk factors for suicidal ideation in patients with schizophrenia. Psychiatry Res., 2019, 271, 195-199. doi: 10.1016/j.psychres.2018.11.051 PMID: 30500709
  3. Xiu, M.H.; Lang, X.; Chen, D.C.; Cao, B.; Kosten, T.R.; Cho, R.Y.; Shi, H.; Wei, C.W.; Wu, A.S.; Zhang, X.Y. Cognitive deficits and clinical symptoms with hippocampal subfields in first-episode and never-treated patients with Schizophrenia. Cereb. Cortex, 2021, 31(1), 89-96. doi: 10.1093/cercor/bhaa208 PMID: 32901269
  4. Xiu, M.H.; Li, Z.; Chen, D.C.; Chen, S.; Curbo, M.E.; Wu, H.E.; Tong, Y.S.; Tan, S.P.; Zhang, X.Y. Interrelationships between BDNF, superoxide dismutase, and cognitive impairment in drug-naive first-episode patients with Schizophrenia. Schizophr. Bull., 2020, 46(6), 1498-1510. doi: 10.1093/schbul/sbaa062 PMID: 32390043
  5. Šagud, M.; Vuksan-Ćusa, B.; Jakšić, N.; Mihaljević-Peleš, A.; Rojnić, K.M.; Pivac, N. Smoking in Schizophrenia: An updated review. Psychiatr. Danub., 2018, 30(Suppl. 4), 216-223. PMID: 29864763
  6. Ding, J.B.; Hu, K. Cigarette smoking and schizophrenia: Etiology, clinical, pharmacological, and treatment implications. Schizophr. Res. Treatment, 2021, 2021, 1-8. doi: 10.1155/2021/7698030 PMID: 34938579
  7. Changeux, J.P. Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice. Nat. Rev. Neurosci., 2010, 11(6), 389-401. doi: 10.1038/nrn2849 PMID: 20485364
  8. Dome, P.; Lazary, J.; Kalapos, M.P.; Rihmer, Z. Smoking, nicotine and neuropsychiatric disorders. Neurosci. Biobehav. Rev., 2010, 34(3), 295-342. doi: 10.1016/j.neubiorev.2009.07.013 PMID: 19665479
  9. Zhu, M.H.; Liu, Z.J.; Hu, Q.Y.; Yang, J.Y.; Jin, Y.; Zhu, N.; Huang, Y.; Shi, D.H.; Liu, M.J.; Tan, H.Y.; Zhao, L.; Lv, Q.Y.; Yi, Z.H.; Wu, F.C.; Li, Z.Z. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: A 12-week randomized, double-blind, placebo-controlled trial. Mil. Med. Res., 2022, 9(1), 59. doi: 10.1186/s40779-022-00420-0 PMID: 36253804
  10. Addington, J.; el-Guebaly, N.; Campbell, W.; Hodgins, D.C.; Addington, D. Smoking cessation treatment for patients with schizophrenia. Am. J. Psychiatry, 1998, 155(7), 974-975. doi: 10.1176/ajp.155.7.974 PMID: 9659869
  11. Sandyk, R. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int. J. Neurosci., 1993, 70(3-4), 193-197. doi: 10.3109/00207459309000574 PMID: 8063538
  12. Taiminen, T.J.; Salokangas, R.K.R.; Saarijärvi, S.; Niemi, H.; Lehto, H.; Ahola, V.; Syvälahti, E. Smoking and cognitive deficits in schizophrenia: A pilot study. Addict. Behav., 1998, 23(2), 263-266. doi: 10.1016/S0306-4603(97)00028-2 PMID: 9573430
  13. Dépatie, L.; O’Driscoll, G.A.; Holahan, A.L.; Atkinson, V.; Thavundayil, J.X.; Kin, N.N.; Lal, S. Nicotine and behavioral markers of risk for schizophrenia: A double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology, 2002, 27(6), 1056-1070. doi: 10.1016/S0893-133X(02)00372-X PMID: 12464463
  14. Williams, J.M.; Ziedonis, D. Addressing tobacco among individuals with a mental illness or an addiction. Addict. Behav., 2004, 29(6), 1067-1083. doi: 10.1016/j.addbeh.2004.03.009 PMID: 15236808
  15. Barr, A.M.; Procyshyn, R.M.; Hui, P.; Johnson, J.L.; Honer, W.G. Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophr. Res., 2008, 100(1-3), 252-260. doi: 10.1016/j.schres.2007.11.027 PMID: 18178062
  16. Goff, D.C.; Henderson, D.C.; Amico, E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am. J. Psychiatry, 1992, 149(9), 1189-1194. doi: 10.1176/ajp.149.9.1189 PMID: 1503131
  17. Cecerska-Heryć, E.; Polikowska, A.; Serwin, N.; Roszak, M.; Grygorcewicz, B.; Heryć, R.; Michalczyk, A.; Dołęgowska, B. Importance of oxidative stress in the pathogenesis, diagnosis, and monitoring of patients with neuropsychiatric disorders, a review. Neurochem. Int., 2022, 153, 105269. doi: 10.1016/j.neuint.2021.105269 PMID: 34971747
  18. Murray, A.J.; Rogers, J.C.; Katshu, M.Z.U.H.; Liddle, P.F.; Upthegrove, R. Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front. Psychiatry, 2021, 12, 703452. doi: 10.3389/fpsyt.2021.703452 PMID: 34366935
  19. Kim, K.B.; Lee, B.M. Oxidative stress to DNA, protein, and antioxidant enzymes (superoxide dismutase and catalase) in rats treated with benzo(a)pyrene. Cancer Lett., 1997, 113(1-2), 205-212. doi: 10.1016/S0304-3835(97)04610-7 PMID: 9065823
  20. Yao, J.K.; Keshavan, M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: An integrative view. Antioxid. Redox Signal., 2011, 15(7), 2011-2035. doi: 10.1089/ars.2010.3603 PMID: 21126177
  21. Wu, J.Q.; Kosten, T.R.; Zhang, X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 46, 200-206. doi: 10.1016/j.pnpbp.2013.02.015 PMID: 23470289
  22. MacNEE. W.; Rahman, I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 1999, 160(5 Pt 2), S58-S65. doi: 10.1164/ajrccm.160.supplement_1.15 PMID: 10556172
  23. Liu, H.; Yu, R.; Gao, Y.; Li, X.; Guan, X.; Thomas, K.; Xiu, M.; Zhang, X. Antioxidant enzymes and weight gain in drug-naive first episode schizophrenia patients treated with risperidone for 12 weeks: A prospective longitudinal study. Curr. Neuropharmacol., 2022, 20(9), 1774-1782. PMID: 34544343
  24. Li, X.R.; Xiu, M.H.; Guan, X.N.; Wang, Y.C.; Wang, J.; Leung, E.; Zhang, X.Y. Altered antioxidant defenses in drug-naive first episode patients with schizophrenia are associated with poor treatment response to risperidone: 12-week results from a prospective longitudinal study. Neurotherapeutics, 2021, 18(2), 1316-1324. doi: 10.1007/s13311-021-01036-3 PMID: 33791970
  25. Morrow, J.D.; Frei, B.; Longmire, A.W.; Gaziano, J.M.; Lynch, S.M.; Shyr, Y.; Strauss, W.E.; Oates, J.A.; Roberts, L.J. II Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med., 1995, 332(18), 1198-1203. doi: 10.1056/NEJM199505043321804 PMID: 7700313
  26. Montuschi, P.; Collins, J.; Ciabattoni, G.; Lazzeri, N.; Corradi, M.; Kharitonov, S.A.; Barnes, P.J. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med., 2000, 162(3), 1175-1177. doi: 10.1164/ajrccm.162.3.2001063 PMID: 10988150
  27. MacNee, W. Oxidants/Antioxidants and COPD. Chest, 2000, 117(5)(Suppl. 1), 303S-317S. doi: 10.1378/chest.117.5_suppl_1.303S-a PMID: 10843965
  28. Kirkham, P.; Rahman, I. Oxidative stress in asthma and COPD: Antioxidants as a therapeutic strategy. Pharmacol. Ther., 2006, 111(2), 476-494. doi: 10.1016/j.pharmthera.2005.10.015 PMID: 16458359
  29. James, R.W.; Leviev, I.; Righetti, A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation, 2000, 101(19), 2252-2257. doi: 10.1161/01.CIR.101.19.2252 PMID: 10811591
  30. Ahmadi-Motamayel, F.; Falsafi, P.; Goodarzi, M.T.; Poorolajal, J. Evaluation of salivary catalase, vitamin C, and alpha-amylase in smokers and non-smokers: A retrospective cohort study. J. Oral Pathol. Med., 2017, 46(5), 377-380. doi: 10.1111/jop.12495 PMID: 27800633
  31. Northrop-Clewes, C.A.; Thurnham, D.I. Monitoring micronutrients in cigarette smokers. Clin. Chim. Acta, 2007, 377(1-2), 14-38. doi: 10.1016/j.cca.2006.08.028 PMID: 17045981
  32. Garg, N.; Singh, R.; Dixit, J.; Jain, A.; Tewari, V. Levels of lipid peroxides and antioxidants in smokers and nonsmokers. J. Periodontal Res., 2006, 41(5), 405-410. doi: 10.1111/j.1600-0765.2006.00889.x PMID: 16953817
  33. Kanehira, T.; Shibata, K.; Kashiwazaki, H.; Inoue, N.; Morita, M. Comparison of antioxidant enzymes in saliva of elderly smokers and non-smokers. Gerodontology, 2006, 23(1), 38-42. doi: 10.1111/j.1741-2358.2006.00077.x PMID: 16433640
  34. Abdolsamadi, H.R.; Goodarzi, M.T.; Mortazavi, H.; Robati, M.; Ahmadi-Motemaye, F. Comparison of salivary antioxidants in healthy smoking and non-smoking men. Chang Gung Med. J., 2011, 34(6), 607-611. PMID: 22196063
  35. Ahmadi-Motamayel, F.; Falsafi, P.; Abolsamadi, H.; Goodarzi, M.T.; Poorolajal, J. Evaluation of salivary antioxidants and oxidative stress markers in male smokers. Comb. Chem. High Throughput Screen., 2019, 22(7), 496-501. doi: 10.2174/1386207322666190806123616 PMID: 31385764
  36. Şenyurt, M.; Aybek, H.; Herken, H.; Kaptanoglu, B.; Korkmaz, A. Evaluation of oxidative status in patients treated with electroconvulsive therapy. Clin. Psychopharmacol. Neurosci., 2017, 15(1), 40-46. doi: 10.9758/cpn.2017.15.1.40 PMID: 28138109
  37. Liu, H.; Liu, H.; Jiang, S.; Su, L.; Lu, Y.; Chen, Z.; Li, X.; Li, X.; Wang, X.; Xiu, M.; Zhang, X. Sex-specific association between antioxidant defense system and therapeutic response to risperidone in schizophrenia: A prospective longitudinal study. Curr. Neuropharmacol., 2022, 20(9), 1793-1803. doi: 10.2174/1570159X19666211111123918 PMID: 34766896
  38. Virit, O.; Altindag, A.; Yumru, M.; Dalkilic, A.; Savas, H.A.; Selek, S.; Erel, O.; Herken, H. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology, 2009, 60(2), 87-93. doi: 10.1159/000239684 PMID: 19776652
  39. Li, X.F.; Zheng, Y.L.; Xiu, M.H.; Chen, D.C.; Kosten, T.R.; Zhang, X.Y. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35(4), 1064-1067. doi: 10.1016/j.pnpbp.2011.03.001 PMID: 21392552
  40. Möller, H.J.; Czobor, P. Pharmacological treatment of negative symptoms in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 2015, 265(7), 567-578. doi: 10.1007/s00406-015-0596-y PMID: 25895634
  41. Al-chalabi, B.M.; Thanoon, I.A.J.; Ahmed, F.A. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology, 2009, 59(1), 8-11. doi: 10.1159/000202823 PMID: 19221442
  42. Aringhieri, S.; Carli, M.; Kolachalam, S.; Verdesca, V.; Cini, E.; Rossi, M.; McCormick, P.J.; Corsini, G.U.; Maggio, R.; Scarselli, M. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol. Ther., 2018, 192, 20-41. doi: 10.1016/j.pharmthera.2018.06.012 PMID: 29953902
  43. Shiina, A.; Shirayama, Y.; Niitsu, T.; Hashimoto, T.; Yoshida, T.; Hasegawa, T.; Haraguchi, T.; Kanahara, N.; Shiraishi, T.; Fujisaki, M.; Fukami, G.; Nakazato, M.; Iyo, M.; Hashimoto, K. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann. Gen. Psychiatry, 2010, 9(1), 27. doi: 10.1186/1744-859X-9-27 PMID: 20573264
  44. Haslemo, T.; Eikeseth, P.H.; Tanum, L.; Molden, E.; Refsum, H. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur. J. Clin. Pharmacol., 2006, 62(12), 1049-1053. doi: 10.1007/s00228-006-0209-9 PMID: 17089108
  45. Schoretsanitis, G.; Haen, E.; Stegmann, B.; Hiemke, C.; Gründer, G.; Paulzen, M. Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism. Schizophr. Res., 2017, 185, 51-57. doi: 10.1016/j.schres.2016.12.016 PMID: 27993531
  46. Zhang, X.Y.; Chen, D.C.; Xiu, M.H.; Haile, C.N.; Sun, H.; Lu, L.; Kosten, T.A.; Kosten, T.R. Cigarette smoking and cognitive function in Chinese male schizophrenia: A case-control study. PLoS One, 2012, 7(5), e36563. doi: 10.1371/journal.pone.0036563 PMID: 22570726
  47. Koga, M.; Serritella, A.V.; Sawa, A.; Sedlak, T.W. Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophr. Res., 2016, 176(1), 52-71. doi: 10.1016/j.schres.2015.06.022 PMID: 26589391
  48. Wang, K.; Xiu, M.; Su, X.; Wu, F.; Zhang, X. Association between changes in total antioxidant levels and clinical symptom improvement in patients with antipsychotic-naïve first-episode schizophrenia after 3 months of risperidone monotherapy. Antioxidants (Basel), 2022, 11(4), 646. doi: 10.3390/antiox11040646 PMID: 35453331
  49. Cooper, J.; Mancuso, S.G.; Borland, R.; Slade, T.; Galletly, C.; Castle, D. Tobacco smoking among people living with a psychotic illness: The second Australian survey of psychosis. Aust. N. Z. J. Psychiatry, 2012, 46(9), 851-863. doi: 10.1177/0004867412449876 PMID: 22645396
  50. Ischemia-modified albumin: A unique marker of global metabolic risk in schizophrenia and mood disorders. Psychiatry and Clinical Psychopharmacology, 2019, 29(2), 7.
  51. Ballesteros, A.; Jiang, P.; Summerfelt, A.; Du, X.; Chiappelli, J.; O’Donnell, P.; Kochunov, P.; Hong, L.E. No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia. Schizophr. Res., 2013, 146(1-3), 184-189. doi: 10.1016/j.schres.2013.02.001 PMID: 23466187
  52. Gould, N.S.; Min, E.; Gauthier, S.; Martin, R.J.; Day, B.J. Lung glutathione adaptive responses to cigarette smoke exposure. Respir. Res., 2011, 12(1), 133. doi: 10.1186/1465-9921-12-133 PMID: 21982222
  53. Zhang, X.Y.; Tan, Y.L.; Zhou, D.F.; Haile, C.N.; Wu, G.Y.; Cao, L.Y.; Kosten, T.A.R.; Kosten, T. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology, 2007, 32(9), 2020-2024. doi: 10.1038/sj.npp.1301317 PMID: 17228336
  54. Grenhoff, J.; Aston-Jones, G.; Svensson, T.H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol. Scand., 1986, 128(3), 351-358. doi: 10.1111/j.1748-1716.1986.tb07988.x PMID: 3788613
  55. Hall, R.G.; Duhamel, M.; McClanahan, R.; Miles, G.; Nason, C.; Rosen, S.; Schiller, P.; Tao-Yonenaga, L.; Hall, S.M. Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. J. Nerv. Ment. Dis., 1995, 183(7), 468-471. doi: 10.1097/00005053-199507000-00008 PMID: 7623020
  56. Al-Halabí, S.; Fernández-Artamendi, S.; Díaz-Mesa, E.M.; García-Álvarez, L.; Flórez, G.; Martínez-Santamaría, E.; Arrojo, M.; Saiz, P.A.; García-Portilla, M.P.; Bobes, J. Tobacco and cognitive performance in schizophrenia patients: the design of the COGNICO study. Adicciones, 2016, 29(1), 6-12. PMID: 27391843
  57. Oliveira, R.M.; Siqueira Júnior, A.C.; Santos, J.L.F.; Furegato, A.R.F. Nicotine dependence in the mental disorders, relationship with clinical indicators, and the meaning for the user. Rev. Lat. Am. Enfermagem, 2014, 22(4), 685-692. doi: 10.1590/0104-1169.3549.2468 PMID: 25296154
  58. Drew, A.E.; Derbez, A.E.; Werling, L.L. Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse, 2000, 38(1), 10-16. doi: 10.1002/1098-2396(200010)38:13.0.CO;2-T PMID: 10941136
  59. Glassman, A.H. Cigarette smoking: Implications for psychiatric illness. Am. J. Psychiatry, 1993, 150(4), 546-553. doi: 10.1176/ajp.150.4.546 PMID: 8465868
  60. Nomikos, G.G.; Schilström, B.; Hildebrand, B.E.; Panagis, G.; Grenhoff, J.; Svensson, T.H. Role of α7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav. Brain Res., 2000, 113(1-2), 97-103. doi: 10.1016/S0166-4328(00)00204-7 PMID: 10942036
  61. Patkar, A.A.; Gopalakrishnan, R.; Lundy, A.; Leone, F.T.; Certa, K.M.; Weinstein, S.P. Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. J. Nerv. Ment. Dis., 2002, 190(9), 604-610. doi: 10.1097/00005053-200209000-00005 PMID: 12357094
  62. Lohr, J.; Flynn, K. Smoking and schizophrenia. Schizophr. Res., 1992, 8(2), 93-102. doi: 10.1016/0920-9964(92)90024-Y PMID: 1360812
  63. Aguilar, M.C.; Gurpegui, M.; Diaz, F.J.; De Leon, J. Nicotine dependence and symptoms in schizophrenia. Br. J. Psychiatry, 2005, 186(3), 215-221. doi: 10.1192/bjp.186.3.215 PMID: 15738502
  64. Dixon, L.; Medoff, D.R.; Wohlheiter, K.; Dixon, L.; Medoff, D.R.; Wohlheiter, K.; DiClemente, C.; Goldberg, R.; Kreyenbuhl, J.; Adams, C.; Lucksted, A.; Davin, C. Correlates of severity of smoking among persons with severe mental illness. Am. J. Addict., 2007, 16(2), 101-110. doi: 10.1080/10550490601184415 PMID: 17453611
  65. Barnes, M.; Lawford, B.R.; Burton, S.C.; Heslop, K.R.; Noble, E.P.; Hausdorf, K.; Young, R.M. Smoking and schizophrenia: Is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Aust. N. Z. J. Psychiatry, 2006, 40(6-7), 575-580. doi: 10.1080/j.1440-1614.2006.01841.x PMID: 16756583
  66. Krishnadas, R.; Jauhar, S.; Telfer, S.; Shivashankar, S.; McCreadie, R.G. Nicotine dependence and illness severity in schizophrenia. Br. J. Psychiatry, 2012, 201(4), 306-312. doi: 10.1192/bjp.bp.111.107953 PMID: 22878134

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers